Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

• Conditions: Hematologic Malignancies; Solid Tumors

• Registration Number: NCT06925685
• Lead Sponsor: Allogene Therapeutics

Brief Summary

An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-01-31
• Status Verified: 2025-04
• Study First Submitted: 2025-04-07
• Study First Submitted QC: 2025-04-07
• Last Update Submitted: 2025-04-07
• Study First Posted: 2025-04-13
• Last Update Posted: 2025-04-13
• Primary Completion: 2039-01
• Study Completion: 2039-01

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study

Exclusion Criteria

• Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs	Up to 15 years post treatment with allogeneic CAR T-cell product
Overall survival (OS)	Up to 15 years post treatment with allogeneic CAR T cell product
Presence of replication competent lentivirus (RCL) in blood	Up to 15 years post treatment with allogeneic CAR T cell product

Trial Locations

Locations (1)

Circuit Clinical; 🇺🇸 Buffalo, New York, United States